Industry Collaboration Index 2026 · University profile
Poland · Europe
Medical University of Lodz is ranked #652 of 1,038. Its strongest pillar is durability (84): 21 of its company groups are sustained partners (five or more joint works in three or more of the five years). It is held back most by breadth (10): partners concentrated in a few research fields; and by scale (36): a network of 51 company groups on two or more joint works.
Research Collaboration Index 2026: #880 of 1,195 · View the RCI profile →
Why this position
How often it co-authors with companies, compared with what its own mix of research fields would predict; size makes no difference. 358 verified works against about 409 expected for its fields (0.88 times the expected rate).
How much of its industry work sits in sustained partnerships with the same company group. 21 sustained partnerships: five or more joint works in three or more of the five years.
The size of its industry network: company groups on two or more works, sustained partnerships, and its place in the worldwide network of universities and companies. 51 company groups on two or more joint works; 21 sustained partnerships.
How varied its partners are, judged by each company's main research field. Measured across the main research fields of all the company groups it worked with.
Each pillar is a percentile among the 1,038 ranked universities: a value of 80 means a higher value than about 80 in every 100 of them. The ICI score (42.4) is the weighted average of the four percentiles. Rank 652 of 1,038 overall; 2 of 14 in Poland; 270 of 388 in Europe. Standing bands: Platinum for ranks 1 to 100, Gold 101 to 300, Silver 301 to 600. How the index is built →
In numbers
In Poland
Where it works with industry
Verified industry works by sector, with its position in each sector ranking. A university is ranked in a sector once it has at least 20 verified works there; sectors with fewer than 50 eligible universities are provisional.
121.5 of its 358 verified industry works fall within the 21 sectors. The rest have research topics that belong to no industry sector (basic science, for example) or are consortium papers with 100 or more authors, which the sector indices leave out; all of them count fully in the overall index.
Who it works with
Medical University of Lodz co-authored verified work with 152 company groups, consortium papers aside: 51 of them on two or more works, and 21 as sustained partners.
| Company group | Based in | Company's main research field | Joint works | Years with a joint work |
|---|---|---|---|---|
| AstraZeneca | United Kingdom | Medicine | 57 | 5 of 5 |
| Syreon Research Institute | Hungary | Economics, Econometrics and Finance | 18 | 5 of 5 |
| Johnson & Johnson | United States | Medicine | 17 | 5 of 5 |
| AbbVie | United States | Medicine | 17 | 5 of 5 |
| GlaxoSmithKline | United Kingdom | Medicine | 11 | 4 of 5 |
| Pfizer | United States | Medicine | 10 | 4 of 5 |
| Regeneron | United States | Medicine | 10 | 5 of 5 |
| Medtronic | Ireland | Medicine | 10 | 5 of 5 |
| Takeda | Japan | Chemistry | 10 | 3 of 5 |
| Novartis | Switzerland | Medicine | 10 | 5 of 5 |
| Novo Nordisk | Denmark | Biochemistry, Genetics and Molecular Biology | 10 | 4 of 5 |
| Sanofi | France | Medicine | 9 | 5 of 5 |
A company group brings together a company's subsidiaries and research labs under one name. A work counts half when its only company author also holds a post at this university. Consortium papers with 100 or more authors are left out of this table.
Examples of its work with industry
Its most-cited verified works with 30 or fewer authors, leaving out guidelines and consensus statements. Citation counts are those of the open scholarly record at harvest. Each title links to the work.
Over time
2025 is not yet complete: papers published late in the year are still being added to the open record, and coverage may not be equally complete for every university, so compare years with care. A work counts half when its only company author also holds a post at the university, so some totals end in .5.
Clinical trials (reported, not scored)
Trials starting 2021 to 2025 in ClinicalTrials.gov in which a company and this university are the sponsor and a collaborator. Names are matched exactly, so a trial registered only under an affiliated hospital's own name is not counted here, and the count can be well below the university's real trial activity. Trials do not enter the score.
Examples:
Funded partnerships (reported, not scored)
Horizon 2020 and Horizon Europe projects starting 2021-2025 in which this university and at least one company take part (63 distinct companies). Most frequent: Eli Lilly and Company, Lilly Deutschland GmbH, Pfizer R&d Uk Limited, Pfizer Inc, Pfizer Limited, Novo Nordisk A/s.
Shown for context from the public grant registries; they do not enter the score in Edition 1. Comparable open registries of company partners exist for the European Union and the United Kingdom but not yet for most other research systems, and in some countries national research organisations take part on behalf of university laboratories, so these counts are not comparable between countries.
Funded and co-publishing. Of the funded company partners that match an ICI company group, 8 also appear in this university's verified co-authorship record (Medtronic, Pfizer, Johnson & Johnson, Fresenius Medical Care, Boehringer Ingelheim, IQVIA) and 9 are funded partners not yet visible in it. About 43% of funded company names could be matched to a company group; the rest are counted, not guessed. Sources: UKRI Gateway to Research harvested 4 Oct 2026; CORDIS bulk files of 2026-10-12 (latest record update 2026-06-10). Funded partnerships cover UK (UKRI Gateway to Research) and EU (Horizon 2020 and Horizon Europe, CORDIS) projects starting 2021 to 2025 only. They are reported, never scored, and a funder record outside these two sources is not visible here.
Evidence checked
Each counted link (one work, this university and one company) was confirmed against the affiliation text its author wrote; 304 of 892 candidate links were set aside.
If a partner is missing or should not be here, send the evidence; corrections are free and reviewed against the public record.
GRP Partnership Intelligence Platform
This profile is free and public, and it stays that way. Beyond it, the GRP Partnership Intelligence Platform, a partner service arranged with each university, sets your record in both GRP indices beside the peers you choose: the universities and companies your peers work with that you do not, live funding calls matched to your strengths, the EU projects your peers have won, and a brief ready for your executive. It opens to partner universities on Monday 19 October 2026: enquire, and the GRP team will confirm availability and pricing for your university.
Request first access → See what is inside →
The platform cannot move any university's position, band or score.
In the Research Collaboration Index 2026, Medical University of Lodz ranks #880 of 1,195. It measures the whole research network, not only industry.
Something wrong? Every figure comes from the public record and can be checked. If a partner is missing or should not be there, tell us and we will review it with the evidence. The 2027 edition will be calculated with the same published methodology. The window for universities to submit data for it is open now: submit data for the 2027 edition. The index is free, public and independent. No commercial relationship with any university or company changes any position, and no one can pay to be included, excluded or moved.